Payment overview · 2025
General Payments
$5,731.67
318 reported records · 14 companies
Healthcare provider profile · identity verified
Marvin Baula, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · MIDDLETOWN, OH · NPI 1104156819
Verified facts
What the public records show
CMS Open Payments records show Marvin Baula, M.D. received $5,731.67 in general payments during 2025 across 318 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 16.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Invega Sustenna, Rexulti, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Vraylar by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 31 records involving 31 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Invega Sustenna by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Invega Sustenna by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Rexulti by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $947.31 | 16.5% | 50 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $869.48 | 15.2% | 32 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $625.45 | 10.9% | 26 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $596.51 | 10.4% | 17 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $583.58 | 10.2% | 42 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $518.09 | 9.0% | 29 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $470.46 | 8.2% | 36 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $455.14 | 7.9% | 36 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $322.15 | 5.6% | 28 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $195.90 | 3.4% | 15 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $70.07 | 1.2% | 3 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.00 | 0.6% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $23.22 | 0.4% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $18.31 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $5,727.88 | 317 |
| Education | $3.79 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $947.31 | 50 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $869.48 | 32 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $625.45 | 26 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $475.95 | 10 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $470.46 | 36 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $455.14 | 36 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $415.95 | 29 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $393.57 | 28 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $392.27 | 27 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $386.56 | 17 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $303.42 | 28 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $214.63 | 15 | 2025 |
Source payment records
|
|||||
| INVEGA TRINZA Normalized: invega trinza |
Drug | Janssen Pharmaceuticals, Inc | $181.83 | 7 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $167.63 | 13 | 2025 |
Source payment records
|
|||||
| ARISTADA INITIO Normalized: aristada initio |
Drug | Alkermes, Inc. | $124.52 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $120.56 | 7 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $101.46 | 7 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $70.07 | 3 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $36.00 | 2 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $23.22 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $16.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INVEGA SUSTENNA invega sustenna |
2025 | Invega Sustenna | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 73 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 62 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
62 | 12 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 31 supporting records · 31 recipient NPIs · example record 1174584421 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
73 | 12 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
73 | 12 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 618 | 72 |
| Trazodone Hcl | Trazodone Hcl | 360 | 55 |
| Clonazepam | Clonazepam | 304 | 42 |
| Aripiprazole | Aripiprazole | 288 | 38 |
| Quetiapine Fumarate | Quetiapine Fumarate | 256 | 36 |
| Bupropion Xl | Bupropion Hcl | 221 | 26 |
| Lamotrigine | Lamotrigine | 205 | 23 |
| Sertraline Hcl | Sertraline Hcl | 205 | 35 |
| Prazosin Hcl | Prazosin Hcl | 184 | 26 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 173 | 30 |
| Risperidone | Risperidone | 162 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 160 | 18 |
| Buspirone Hcl | Buspirone Hcl | 158 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 147 | 21 |
| Lorazepam | Lorazepam | 139 | 17 |
| Mirtazapine | Mirtazapine | 134 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 127 | 23 |
| Olanzapine | Olanzapine | 125 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 119 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 118 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 110 | 20 |
| Benztropine Mesylate | Benztropine Mesylate | 106 | 11 |
| Oxcarbazepine | Oxcarbazepine | 90 | 11 |
| Lurasidone Hcl | Lurasidone Hcl | 84 | 17 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 79 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 76 | suppressed |
| Rexulti | Brexpiprazole | 73 | 12 |
| Gabapentin | Gabapentin | 72 | 12 |
| Diazepam | Diazepam | 66 | 12 |
| Vraylar | Cariprazine Hcl | 62 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 11 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 60 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 57 | 11 |
| Divalproex Sodium | Divalproex Sodium | 52 | suppressed |
| Temazepam | Temazepam | 49 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 46 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 46 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 43 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 40 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 36 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Haloperidol | Haloperidol | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Paliperidone Er | Paliperidone | 29 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 27 | suppressed |
| Clozapine | Clozapine | 26 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 23 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Fluvoxamine Maleate Er | Fluvoxamine Maleate | 23 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Austedo | Deutetrabenazine | 13 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 13 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 13 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 12 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,731.67 · 318 records | E.R. Squibb & Sons, L.L.C. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, ARISTADA INITIO, AUSTEDO XR, Auvelity, BRIXADI, CAPLYTA, COBENFY, FANAPT, HETLIOZ, INGREZZA, INVEGA SUSTENNA, INVEGA TRINZA, LYBALVI, PONVORY, Qelbree, REXULTI, SPRAVATO, TREMFYA, UZEDY, VRAYLAR | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Invega Sustenna play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error